B+
Bull case
30%
Probability
Target price
$15.50
+34.2% vs current
TRLV
Trulieve CannabisANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-12
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$13.00
+12.6% vs current
B-
Bear case
25%
Probability
Target price
$8.50
-26.4% vs current
AI sentiment snapshot
Latest data as of 2026-06-11
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+68.9
Score
AI commentary
Primary-source tone is constructive because the latest company-reported quarter showed profitability, strong EBITDA, and free cash flow, but external confirmation is thin: the packet has no recent news set, no social coverage with sufficient data, and no analyst-revision detail. That supports a cautious positive monitoring stance rather than a high-conviction momentum call.
RankAlpha Sentiment Codex - 2026-06-11
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-29eventFederal marijuana rescheduling process and June 29 hearingHigh impact
Management said the Trump Administration reclassified medical marijuana to Schedule III and that a broader review hearing begins on June 29, 2026; Trulieve also said it filed DEA registration applications covering 206 retail locations, creating a potentially material tax and operating-structure catalyst if the process advances. [#SEC-8K-2026-05-07]
2026-08-12catalystQ1 profitability and free-cash-flow durabilityHigh impact
Q1 2026 showed $287 million revenue, 59% gross margin, $2 million net income, $100 million adjusted EBITDA, $56 million operating cash flow, $42 million free cash flow, and $353 million cash, which supports a near-term rerating if investors gain confidence these margins and cash metrics are sustainable. [#SEC-8K-2026-05-07]
2026-12-31catalystRetail footprint and new-market optionalityHigh impact
The company exited 2025 with conditional approval for a Texas Compassionate Use Program dispensing license, 233 retail locations, and refinanced debt with secured notes due 2030; if Trulieve converts footprint scale into higher-volume growth without margin erosion, the equity could close part of its gap to the packet's median target. [#SEC-8K-2026-02-26]
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-11 • Updated nightlySource: Internal modelMethodology